Atavistik Bio Secures $120 Million: Advancing Precision Therapies for HHT and MPNs
December 28, 2025, 3:33 pm
Atavistik Bio secured $120 million in Series B funding. This substantial capital will advance two crucial therapeutic programs. An oral AKT1-selective inhibitor targets Hereditary Hemorrhagic Telangiectasia (HHT). A JAK2 V617F mutant-selective inhibitor program tackles myeloproliferative neoplasms (MPNs). Both aim for clinical proof-of-concept milestones. The HHT program is set to enter clinical trials in the first half of 2026. This financing underscores investor confidence in Atavistik’s proprietary AMPS platform. Their "precision allostery" approach seeks superior efficacy and tolerability. This move promises significant advancements for patients suffering from these challenging diseases, currently lacking optimal treatments.
The Cambridge, MA-based biotech firm, Atavistik Bio, achieved a major financial milestone. It successfully raised $120 million in Series B financing. This substantial capital injection provides critical resources. It will drive the company's innovative drug development forward. This round saw strong backing from both new and existing investors. Their commitment underscores the transformative potential of Atavistik's scientific endeavors.
Nextech Invest and The Column Group co-led the financing. These firms bring significant experience in biotech investment. Existing investor Lux Capital also participated. New investor Regeneron Ventures joined the round. This diversified investor base signals robust confidence. They believe in Atavistik's unique scientific approach and its promising pipeline potential. The funds are earmarked for strategic clinical advancement. This investment fuels a new era of targeted therapeutics.
Atavistik Bio focuses these funds on two primary programs. Both target severe diseases with high unmet needs. The goal is to move these programs through clinical proof-of-concept milestones. This is a critical stage in drug development. Success here validates the therapeutic hypothesis. It moves treatments closer to patients. These programs represent significant leaps in medical innovation.
One key program addresses Hereditary Hemorrhagic Telangiectasia, or HHT. HHT is a rare, inherited vascular disorder. It causes abnormal blood vessel formation throughout the body. Patients experience frequent, often severe bleeding. This can lead to chronic anemia and serious organ complications. Current treatments largely manage symptoms. Approved disease-modifying therapies remain elusive, creating a significant patient burden. This highlights the urgent need for new solutions.
Atavistik Bio pursues an oral, AKT1-selective allosteric inhibitor for HHT. This strategy aims for targeted intervention. The AKT1 pathway is implicated in HHT pathology. Selectively modulating AKT1 offers a precise therapeutic window. Previous attempts with pan-AKT inhibitors faced significant challenges. They often caused broad, dose-limiting tolerability issues. Specifically, AKT2-driven hyperglycemia was a common, severe side effect. This severely limited chronic dosing, which is essential for managing HHT. Atavistik's selective AKT1 approach seeks to bypass these hurdles. It offers a potentially disease-modifying treatment, rather than just symptomatic relief. The HHT program is expected to enter the clinic in the first half of 2026. This timeline highlights rapid progression toward human trials.
The second critical program targets myeloproliferative neoplasms, known as MPNs. These are a group of chronic blood cancers. A specific somatic mutation, JAK2 V617F, plays a central role across many MPN subtypes. It drives uncontrolled blood cell production. Existing therapies, primarily non-selective JAK inhibitors, manage symptoms. They often cause side effects due to inhibiting wild-type JAK. These treatments do not effectively address the underlying mutant allele burden. They also struggle to preserve normal blood cell production. Patients still face disease progression and treatment-related toxicities.
Atavistik Bio is developing a JAK2 V617F mutant-selective inhibitor. This precision strategy seeks to improve patient outcomes significantly. A mutant-selective approach could directly reduce the burden of mutated cells in the bone marrow. Crucially, it aims to preserve normal blood cell production. This vital process is regulated by wild-type JAK2. By sparing normal JAK2 function, the therapy aims for improved tolerability. Greater efficacy in targeting the disease root is also a key objective. This innovative approach promises a new, potentially curative, standard for MPN treatment.
The company's scientific edge lies in its proprietary AMPS™ platform. AMPS stands for Allosteric Modulators of Protein Systems. Atavistik describes its methodology as "precision allostery." This platform is specifically designed for discovering and optimizing allosteric small molecules. Allosteric modulation targets unique, regulatory sites on proteins. This differs from traditional active-site blocking drugs. It offers a distinct advantage for achieving selectivity.
This "precision allostery" allows for strong target selectivity. It minimizes off-target effects. This selectivity often translates into vastly improved tolerability profiles. Superior efficacy can also result from a more nuanced modulation of protein function. The AMPS platform represents a significant technological advantage. It enables the development of best-in-class therapeutics. It opens new avenues for drugging previously intractable targets.
The $120 million Series B financing profoundly validates Atavistik Bio's technology. It confirms strong investor confidence in their platform's capabilities. It also highlights the immense potential of their targeted pipeline assets. This investment fuels sustained innovation. Bryan Stuart leads Atavistik Bio as Chief Executive Officer. John A. Josey, PhD, serves as Board Chair. Their experienced leadership guides the company's strategic vision. They drive its mission to deliver impactful new medicines.
Biotech investment continues to flow into promising areas. Rare diseases and oncology remain high priorities for capital deployment. Atavistik's dual focus squarely addresses critical needs in both domains. Their commitment to precise, selective treatments aligns with modern medicine's most advanced directions. The company aims to translate rigorous scientific promise into tangible, life-changing patient benefits.
The upcoming clinical trial for HHT marks a pivotal moment. It represents a significant step towards addressing a global patient population. Over 1.6 million people worldwide currently lack approved, disease-modifying HHT therapies. The potential for such a treatment offers immense hope. It promises a better quality of life. For MPN patients, a more targeted, allele-specific therapy could revolutionize care. It might transform a chronic condition into something more manageable or even curable.
Atavistik Bio is poised for rapid, impactful advancement. Its robust funding, innovative AMPS platform, and targeted pipeline create a powerful combination. The company's ongoing work could redefine treatment landscapes in HHT and MPNs. It embodies the future of precision medicine. Its progress will be closely watched by the medical community. Patients awaiting better options will follow it intently. This is a critical time for Atavistik Bio. It is a critical time for advanced biotech solutions globally.
The Cambridge, MA-based biotech firm, Atavistik Bio, achieved a major financial milestone. It successfully raised $120 million in Series B financing. This substantial capital injection provides critical resources. It will drive the company's innovative drug development forward. This round saw strong backing from both new and existing investors. Their commitment underscores the transformative potential of Atavistik's scientific endeavors.
Nextech Invest and The Column Group co-led the financing. These firms bring significant experience in biotech investment. Existing investor Lux Capital also participated. New investor Regeneron Ventures joined the round. This diversified investor base signals robust confidence. They believe in Atavistik's unique scientific approach and its promising pipeline potential. The funds are earmarked for strategic clinical advancement. This investment fuels a new era of targeted therapeutics.
Atavistik Bio focuses these funds on two primary programs. Both target severe diseases with high unmet needs. The goal is to move these programs through clinical proof-of-concept milestones. This is a critical stage in drug development. Success here validates the therapeutic hypothesis. It moves treatments closer to patients. These programs represent significant leaps in medical innovation.
One key program addresses Hereditary Hemorrhagic Telangiectasia, or HHT. HHT is a rare, inherited vascular disorder. It causes abnormal blood vessel formation throughout the body. Patients experience frequent, often severe bleeding. This can lead to chronic anemia and serious organ complications. Current treatments largely manage symptoms. Approved disease-modifying therapies remain elusive, creating a significant patient burden. This highlights the urgent need for new solutions.
Atavistik Bio pursues an oral, AKT1-selective allosteric inhibitor for HHT. This strategy aims for targeted intervention. The AKT1 pathway is implicated in HHT pathology. Selectively modulating AKT1 offers a precise therapeutic window. Previous attempts with pan-AKT inhibitors faced significant challenges. They often caused broad, dose-limiting tolerability issues. Specifically, AKT2-driven hyperglycemia was a common, severe side effect. This severely limited chronic dosing, which is essential for managing HHT. Atavistik's selective AKT1 approach seeks to bypass these hurdles. It offers a potentially disease-modifying treatment, rather than just symptomatic relief. The HHT program is expected to enter the clinic in the first half of 2026. This timeline highlights rapid progression toward human trials.
The second critical program targets myeloproliferative neoplasms, known as MPNs. These are a group of chronic blood cancers. A specific somatic mutation, JAK2 V617F, plays a central role across many MPN subtypes. It drives uncontrolled blood cell production. Existing therapies, primarily non-selective JAK inhibitors, manage symptoms. They often cause side effects due to inhibiting wild-type JAK. These treatments do not effectively address the underlying mutant allele burden. They also struggle to preserve normal blood cell production. Patients still face disease progression and treatment-related toxicities.
Atavistik Bio is developing a JAK2 V617F mutant-selective inhibitor. This precision strategy seeks to improve patient outcomes significantly. A mutant-selective approach could directly reduce the burden of mutated cells in the bone marrow. Crucially, it aims to preserve normal blood cell production. This vital process is regulated by wild-type JAK2. By sparing normal JAK2 function, the therapy aims for improved tolerability. Greater efficacy in targeting the disease root is also a key objective. This innovative approach promises a new, potentially curative, standard for MPN treatment.
The company's scientific edge lies in its proprietary AMPS™ platform. AMPS stands for Allosteric Modulators of Protein Systems. Atavistik describes its methodology as "precision allostery." This platform is specifically designed for discovering and optimizing allosteric small molecules. Allosteric modulation targets unique, regulatory sites on proteins. This differs from traditional active-site blocking drugs. It offers a distinct advantage for achieving selectivity.
This "precision allostery" allows for strong target selectivity. It minimizes off-target effects. This selectivity often translates into vastly improved tolerability profiles. Superior efficacy can also result from a more nuanced modulation of protein function. The AMPS platform represents a significant technological advantage. It enables the development of best-in-class therapeutics. It opens new avenues for drugging previously intractable targets.
The $120 million Series B financing profoundly validates Atavistik Bio's technology. It confirms strong investor confidence in their platform's capabilities. It also highlights the immense potential of their targeted pipeline assets. This investment fuels sustained innovation. Bryan Stuart leads Atavistik Bio as Chief Executive Officer. John A. Josey, PhD, serves as Board Chair. Their experienced leadership guides the company's strategic vision. They drive its mission to deliver impactful new medicines.
Biotech investment continues to flow into promising areas. Rare diseases and oncology remain high priorities for capital deployment. Atavistik's dual focus squarely addresses critical needs in both domains. Their commitment to precise, selective treatments aligns with modern medicine's most advanced directions. The company aims to translate rigorous scientific promise into tangible, life-changing patient benefits.
The upcoming clinical trial for HHT marks a pivotal moment. It represents a significant step towards addressing a global patient population. Over 1.6 million people worldwide currently lack approved, disease-modifying HHT therapies. The potential for such a treatment offers immense hope. It promises a better quality of life. For MPN patients, a more targeted, allele-specific therapy could revolutionize care. It might transform a chronic condition into something more manageable or even curable.
Atavistik Bio is poised for rapid, impactful advancement. Its robust funding, innovative AMPS platform, and targeted pipeline create a powerful combination. The company's ongoing work could redefine treatment landscapes in HHT and MPNs. It embodies the future of precision medicine. Its progress will be closely watched by the medical community. Patients awaiting better options will follow it intently. This is a critical time for Atavistik Bio. It is a critical time for advanced biotech solutions globally.